Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease.

Neurooncol Adv · 2021 · PMC8134529 · PMID 34042102

Europe PMC DOI

hedged sentences

0.9100

closest p · 18.2× alpha

0.9100

boldest claim

The sentences

showed a trendP = .91not close (p > 0.1)

CIK immunotherapy, cytotoxic lymphocyte (HR = 0.69, 95% CI 0.44–1.10), and cilengitide (HR = 0.79, 95% CI 0.58–1.06) showed a trend toward significant alkylating agents ( P = .91) followed by TTF ( P = .84) and CIK immunotherapy ( P = .78) ranked the first 3 treatments that improved OS ( Figure 4A ).

also in 53,322 other papers

a nonsignificant trendno p-value reported

ICT-107 (dendritic cell vaccine) showed a nonsignificant trend toward improving PFS (HR = 0.57, 95% CI 0.29–1.14).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.